Sambucus nigra agglutinin as a supporter of docetaxel treatment in metastatic prostate cancer
Yazarlar (6)
Doç. Dr. Fadime Mutlu İçduygu Giresun Üniversitesi, Türkiye
Doç. Dr. Asuman ÖZGÖZ Kastamonu Üniversitesi, Türkiye
Doç. Dr. Nesrin İÇLİ Kastamonu Üniversitesi, Türkiye
Hale Şamlı Bursa Uludağ Üniversitesi, Türkiye
Doç. Dr. Kuyaş Hekimler Öztürk Süleyman Demirel University, Faculty Of Medicine, Türkiye
Yaşar Nuri Şahin
Kastamonu Üniversitesi, Türkiye
Makale Türü Özgün Makale (ESCI dergilerinde yayınlanan tam makale)
Dergi Adı Human Gene
Dergi ISSN 2773-0441 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler ESCI
Makale Dili Türkçe Basım Tarihi 12-2023
Cilt / Sayı / Sayfa 38 / 1 / 1–7 DOI 10.1016/j.humgen.2023.201221
Makale Linki https://doi.org/10.1016/j.humgen.2023.201221
Özet
Androgen deprivation therapy (ADT) has been the first treatment for advanced prostate cancer. Although 90% of patients initially respond to ADT, the disease inevitably progresses to castration-resistant prostate cancer (CRPC). Docetaxel was reported to provide significant benefit over other chemotherapeutics in prolonging survival in CRPC. Recently, other chemotherapeutics have been used in cases where docetaxel is insufficient or the patient develops resistance, but yet their efficacy is limited. For this reason, it is necessary to develop docetaxel-based therapy, reduce toxicity, increase treatment efficiency. It has been shown that the non-toxic plant lectin Sambucus nigra agglutinin (SNA) drives ovarian cancer cells to the apoptotic pathway. Increased sialic acid levels in prostate cancer have suggested that SNA lectin, which binds to glycan sialic acid residues, may also have an activating effect on the apoptotic …
Anahtar Kelimeler
Apoptosis | Docetaxel | Plant lectin | Prostate cancer | SNA
Science Direct
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Web of Science 1
Google Scholar 1
Sambucus nigra agglutinin as a supporter of docetaxel treatment in metastatic prostate cancer

Paylaş